Guard Therapeutics International AB (GUARD) AI Stock Analysis

• Market Cap: kr37.41M
• Dividend Yield: N/A
• Average Volume (3M): 44.15K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.67
• Revenue Growth: N/A
• EPS Growth: 0.30%
• Country: SE
• Employees: 12
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.29
• Shares Outstanding: 20,167,631
• 10 Day Avg. Volume: 59,609
• 30 Day Avg. Volume: 44,153
• PEG Ratio: 0.09
• Price to Book (P/B): 5.44
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.18
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: kr2.00 ▲(44.93% Upside)

The score is driven primarily by very weak financial performance (no revenue, ongoing losses, and persistent cash burn with a shrinking equity base), which outweighs only modestly constructive near-term technical signals. Valuation is also constrained by loss-making status (negative P/E) and no dividend yield data.

Positive Factors

Low leverage

Near-zero debt materially reduces solvency and interest-cost risk, giving management structural flexibility to prioritize clinical R&D over fixed financing obligations. For a cash‑intensive biotech, low leverage preserves optionality for partnerships or equity financing during long development cycles.

Improving cash-burn trend

A measurable reduction in free cash outflow and narrower net losses indicates better cost control or program prioritization. Sustained improvement in cash metrics can extend runway, reduce near-term financing frequency, and increase the chance of reaching clinical inflection points without immediate dilutive funding.

Focused renal pipeline

A concentrated strategy targeting AKI and renal disease addresses a persistent, large unmet medical need tied to aging and chronic comorbidities. Specialization can build domain expertise, streamline regulatory strategy, and make the company an attractive partner or acquisition target over the medium term.

Negative Factors

No product revenue

Absence of product-derived revenue means all operations depend on financing rather than self-sustaining cash generation. This structural gap increases dilution and execution risk, since commercialization and durable profitability remain unproven and timelines for revenue are uncertain.

Shrinking equity base

A steep fall in equity reflects cumulative losses and erodes the balance-sheet cushion needed to absorb setbacks. Reduced capital base shortens runway absent fresh funding, increases likelihood of dilutive financings, and weakens resilience to trial delays or higher-than-expected development costs.

Persistent negative cash flow

Chronic negative operating and free cash flow is a structural constraint on execution: it limits ability to fund trials, retain talent, and scale operations without external capital. Ongoing cash burn elevates financing dependency and execution risk over the next several quarters absent material new sources of funding.

Guard Therapeutics International AB Business Overview & Revenue Model

Company Description

Guard Therapeutics International AB (publ), a pharmaceutical company, identifies, develops, and commercializes therapies for the diagnosis and treatment of acute kidney injuries in Sweden. It offers ROSGard, a biological drug candidate that prevents kidney damage by protecting, cleaning, and repairing the exposed cells and tissues. The company was formerly known as A1M Pharma AB (publ) and changed its name to Guard Therapeutics International AB (publ) in October 2019. Guard Therapeutics International AB (publ) was incorporated in 2008 and is based in Stockholm, Sweden.

How the Company Makes Money

Guard Therapeutics primarily makes money through the development and potential commercialization of its drug candidate, ROSgard. Revenue streams include potential milestone payments, royalties, and licensing agreements with pharmaceutical companies upon successful regulatory approval and commercialization. The company may also receive funding through research grants, partnerships, and collaborations with other biotech firms or research institutions. Significant factors contributing to its earnings include the successful advancement of ROSgard through clinical trials and securing strategic partnerships for distribution and marketing.

Guard Therapeutics International AB Financial Statement Overview

Summary

Financials remain very weak with zero reported revenue (2019–2024), persistent operating/net losses, and consistently negative operating and free cash flow (cash burn). While 2024 shows narrowing losses and improved free cash flow versus 2023, equity has fallen sharply (38.0M in 2024 vs 177.4M in 2022), signaling ongoing value erosion and elevated financing/dilution risk despite minimal debt.

Income Statement

The income statement remains very weak, with zero reported revenue across 2019–2024 and persistent, sizable operating and net losses each year. Losses have narrowed versus 2023 (net loss improved from -113.3M to -96.1M in 2024), but profitability is still far from break-even and margins are effectively non-existent given the lack of revenue.

Balance Sheet

The balance sheet benefits from minimal leverage (total debt is effectively zero in recent years), which reduces financial risk. However, equity and assets have declined materially from 2021–2022 levels to 2024 (equity down to 38.0M in 2024 from 177.4M in 2022), reflecting ongoing losses and a shrinking capital base; returns on equity are deeply negative, underscoring continued value erosion.

Cash Flow

Cash generation is a major concern: operating cash flow and free cash flow are consistently negative each year, indicating the business is cash-consuming. There is improvement in 2024 versus 2023 (free cash flow improved from -116.0M to -94.8M), but the company still relies on external funding to sustain operations given persistent cash burn.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	-15.00K	-15.00K	-15.00K	-161.00K
EBITDA	-123.13M	-100.23M	-114.91M	-112.82M	-82.01M	-40.12M
Net Income	-124.12M	-96.07M	-113.32M	-110.76M	-82.16M	-40.29M
Balance Sheet
Total Assets	101.87M	55.74M	85.23M	202.60M	190.44M	91.22M
Cash, Cash Equivalents and Short-Term Investments	100.48M	54.19M	83.74M	201.01M	188.60M	90.04M
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	21.47M	17.77M	18.49M	25.24M	14.66M	11.54M
Stockholders Equity	80.40M	37.97M	66.73M	177.36M	175.78M	79.69M
Cash Flow
Free Cash Flow	-116.98M	-94.75M	-116.05M	-102.14M	-77.59M	-37.96M
Operating Cash Flow	-116.98M	-94.75M	-116.05M	-102.14M	-77.59M	-37.96M
Investing Cash Flow	0.00	0.00	0.00	-1.00K	0.00	118.00K
Financing Cash Flow	126.37M	62.66M	-779.00K	112.60M	176.30M	74.05M

Guard Therapeutics International AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.38
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:GUARD, the sentiment is Negative. The current price of 1.38 is below the 20-day moving average (MA) of 1.85, below the 50-day MA of 1.55, and below the 200-day MA of 13.50, indicating a neutral trend. The MACD of -0.04 indicates Negative momentum. The RSI at 46.05 is Neutral, neither overbought nor oversold. The STOCH value of 44.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:GUARD.

Guard Therapeutics International AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
XBRANE	53 Neutral	kr220.68M	1.19	-16.90%	―	4.64%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CLBIO	50 Neutral	kr426.14M	-17.10	―	―	―	―
GUARD	46 Neutral	kr37.41M	-0.24	-199.25%	―	―	0.30%
IMMU	46 Neutral	kr355.16M	-2.82	-16.51%	―	―	31.37%
IVACC	45 Neutral	kr296.17M	-2.30	-25.66%	―	127.13%	56.91%
ACE	43 Neutral	kr335.57M	-3.08	-79.60%	―	―	31.62%